Filing Flows › Verrica Pharmaceuticals (VRCA) › Q4 2025
Verrica Pharmaceuticals (VRCA) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 11, 2026
Verrica Pharmaceuticals (VRCA) reported revenue of $5.1M for the fourth quarter 2025 (Q4 2025), up 15-fold from a year earlier and -65% from the quarter before. Operating margin was -141.2%, net loss $8.1M (158.6% of revenue).
Verrica Pharmaceuticals, Q4 2025: revenue $5.1M (15× year over year), operating margin -141.2%, net loss $8.1M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.1M | -65% | 15× |
| Operating profit | −$7.2M | -542% | — |
| Net earnings | −$8.1M | — | — |
| Operating cash flow | −$4.6M | -147% | — |
What changed
Revenue was $5.1M in Q4 2025, up 1380% year over year and down 65% from the previous quarter. Product revenue, net was the largest line at 73% of revenue.
Operating costs exceeded revenue by $7.2M, an operating margin of -141.2%. Total costs grew 5% against revenue growth of 1380%. The quarter ended with a net loss of $8.1M, wider than the previous quarter's $274K loss.
Operating cash flow was −$4.6M. Non-cash charges added back $14K of depreciation and $686K of share-based compensation. Working capital and other items added $2.8M.
Questions
What was Verrica Pharmaceuticals' revenue in the fourth quarter 2025?
Verrica Pharmaceuticals (VRCA) reported revenue of $5.1M for the fourth quarter 2025 (Q4 2025), up 15-fold from a year earlier and -65% from the quarter before.
Was Verrica Pharmaceuticals profitable in the fourth quarter 2025?
Operating loss was $7.2M (-141.2% of revenue) and net loss $8.1M.